GYRE

Company Overview — What Does GYRE THERAPEUTICS, INC. Do?

Gyre Therapeutics (“Gyre”) is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (“MASH fibrosis”), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. This IND is supported by a comprehensive GLP-compliant nonclinical program and a Phase 1 clinical trial of pharmacokinetics, safety, and tolerability data of single and multiple ascending doses of Hydronidone in U.S. healthy subjects. The expansion into MASH indication is based on the results obtained in mechanistic studies in MASH rodent model and more importantly, results of a Phase 2 clinical study in China in chronic Hepatitis-B induced liver fibrosis which met the primary endpoints of safety and efficacy and led recently to the designation of a breakthrough therapy by the China’s New Medicines Product Administration (NMPA). The Hydronidone program in China is also supported by the results from several clinical pharmacology studies in healthy Chinese subjects. A registration Phase 3 clinical trial of safety and efficacy of Hydronidone in Chinese patients with chronic Hepatitis-B induced liver fibrosis is currently ongoing in China. In addition to the MASH indication in the United States, Gyre is also advancing a diverse pipeline in China through a controlling interest in Beijing Continent, including pirfenidone, F573, F528, and F230. Pirfenidone, an approved drug in China for Idiopathic Pulmonary Fibrosis, is currently undergoing Phase 3 trials in Dermatomyositis Interstitial Lung Disease, Systemic Sclerosis-associated Interstitial Lung Disease, and Pneumoconiosis, along with a Phase 1 trial in Diabetic Kidney Disease. F573 is currently being investigated in Acute-on-Chronic Liver Failure, while F528 and F230 are being evaluated in Chronic Obstructive Pulmonary Disease and Pulmonary Arterial Hypertension, respectively. GYRE THERAPEUTICS, INC. (GYRE) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Han Ying and employs approximately 40 people, headquartered in Winston-Salem, California. With a market capitalization of $660M, GYRE is one of the notable companies in the Healthcare sector.

GYRE THERAPEUTICS, INC. (GYRE) Stock Rating — Reduce (April 2026)

As of April 2026, GYRE THERAPEUTICS, INC. receives a Reduce rating with a composite score of 36.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.GYRE ranks #3,127 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, GYRE THERAPEUTICS, INC. ranks #459 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

GYRE Stock Price and 52-Week Range

GYRE THERAPEUTICS, INC. (GYRE) currently trades at $7.39. The stock gained $0.15 (2.1%) in the most recent trading session. The 52-week high for GYRE is $11.78, which means the stock is currently trading -37.3% from its annual peak. The 52-week low is $6.11, putting the stock 20.9% above its annual trough. Recent trading volume was 47K shares, suggesting relatively thin trading activity.

Is GYRE Overvalued or Undervalued? — Valuation Analysis

GYRE THERAPEUTICS, INC. (GYRE) carries a value factor score of 46/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 35.80x, compared to the Healthcare sector average of 23.63x — a premium of 52%. The price-to-book ratio stands at 4.57x, versus the sector average of 2.75x. The price-to-sales ratio is 6.20x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, GYRE trades at 41.67x EV/EBITDA, versus 6.34x for the sector.

Overall, GYRE's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

GYRE THERAPEUTICS, INC. Profitability — ROE, Margins, and Quality Score

GYRE THERAPEUTICS, INC. (GYRE) earns a quality factor score of 33/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 12.8%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 10.9% versus the sector average of -33.1%.

On a margin basis, GYRE THERAPEUTICS, INC. reports gross margins of 95.6%, compared to 71.5% for the sector. The operating margin is 14.4% (sector: -66.1%). Net profit margin stands at 17.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 21.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

GYRE Debt, Balance Sheet, and Financial Health

GYRE THERAPEUTICS, INC. has a debt-to-equity ratio of 17.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.60x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $40M.

GYRE has a beta of 1.36, meaning it is more volatile than the broader market — a $10,000 investment in GYRE would be expected to move 35.7% more than the S&P 500 on any given day. The stability factor score for GYRE THERAPEUTICS, INC. is 33/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

GYRE THERAPEUTICS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, GYRE THERAPEUTICS, INC. reported revenue of $105M and earnings per share (EPS) of $0.06. Net income for the quarter was $18M. Gross margin was 95.6%. Operating income came in at $16M.

In FY 2025, GYRE THERAPEUTICS, INC. reported revenue of $117M and earnings per share (EPS) of $0.06. Net income for the quarter was $10M. Gross margin was 95.3%. Revenue grew 10.2% year-over-year compared to FY 2024. Operating income came in at $11M.

In Q3 2025, GYRE THERAPEUTICS, INC. reported revenue of $31M and earnings per share (EPS) of $0.04. Net income for the quarter was $8M. Gross margin was 94.7%. Revenue grew 19.9% year-over-year compared to Q3 2024. Operating income came in at $7M.

In Q2 2025, GYRE THERAPEUTICS, INC. reported revenue of $27M and earnings per share (EPS) of $0.00. Net income for the quarter was $2M. Gross margin was 95.7%. Revenue grew 6.1% year-over-year compared to Q2 2024. Operating income came in at $2M.

Over the past 8 quarters, GYRE THERAPEUTICS, INC. has demonstrated a growth trajectory, with revenue expanding from $25M to $105M. Investors analyzing GYRE stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

GYRE Dividend Yield and Income Analysis

GYRE THERAPEUTICS, INC. (GYRE) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

GYRE Momentum and Technical Analysis Profile

GYRE THERAPEUTICS, INC. (GYRE) has a momentum factor score of 33/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 26/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 50/100 reflects moderate short selling activity.

GYRE vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, GYRE THERAPEUTICS, INC. (GYRE) ranks #459 out of 838 stocks based on the Blank Capital composite score. This places GYRE in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing GYRE against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full GYRE vs S&P 500 (SPY) comparison to assess how GYRE THERAPEUTICS, INC. stacks up against the broader market across all factor dimensions.

GYRE Next Earnings Date

No upcoming earnings date has been announced for GYRE THERAPEUTICS, INC. (GYRE) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy GYRE? — Investment Thesis Summary

The quantitative profile for GYRE THERAPEUTICS, INC. suggests caution. The quality score of 33/100 flags below-average profitability. Momentum is weak at 33/100, a headwind for near-term performance. High volatility (stability score 33/100) increases portfolio risk.

In summary, GYRE THERAPEUTICS, INC. (GYRE) earns a Reduce rating with a composite score of 36.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on GYRE stock.

Related Resources for GYRE Investors

Explore more research and tools: GYRE vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare GYRE head-to-head with peers: GYRE vs AZN, GYRE vs SLGL, GYRE vs VMD.